市場調査報告書：癌の分子標的治療

Abstract

Overview

Introduction

Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Scope

Research and analysis of the MTT pipeline with in-depth clinical and commercial assessment of Phase III candidates
Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events
Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer
Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needs

Report Highlights

329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016.

Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline).

Other candidates holding particular promise include the only preregistered agent - Novartis' s Gleevec-follow-on - Tasigna (nilotinib), Novartis' s mTOR inhibitor Certican (everolimus), and Biogen Idec' s anti-CD23 monoclonal antibody, lumiliximab.

Reasons to Purchase

Acquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline
Identify the key products in late-phase development based on sales forecasts to 2016 and Datamonitor' s drug assessment methodology
Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of analysis
- Datamonitor insight into the molecular targeted therapies market
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline molecular targeted cancer therapies
  - Phase II pipeline molecular targeted cancer therapies
  - Phase I pipeline molecular targeted cancer therapies
- Pipeline by developmental phase and class of drug
  - There are 329 different MTTs in the clinical development pipeline
    - The cell cycle and apoptosis targeted agents make up the largest number of MTTs in the pipeline
  - Segmentation of drugs by developmental phase reflects attrition rate of drug development in the oncology market
    - Targeted therapy remains a promising anticancer drug development strategy
    - Developmental agents by phase for each class
- Pipeline by indication
  - Pipeline MTTs are being investigated in 29 different cancers
    - The ' big four' tumor types are the most popular indications for development
- Pipeline by mode of action
  - Pipeline products are directed against a huge variety and combination of molecular targets
  - The VEGF/VEGFR family remains the focus of development for MTTs
- Pipeline by company
  - There are 175 different companies developing targeted therapies
    - Developmental pipeline dominated by small pharma/biotech players
  - There are 19 companies with MTT products in late-phase development
  - Top three companies in terms of number of pipeline MTT products are Pfizer, AstraZeneca and Novartis
    - Pfizer - 21 MTT pipeline products
    - AstraZeneca - 15 MTT pipeline products
    - Novartis - 12 MTT pipeline products
- Key metrics
- Datamonitor pipeline assessment summary
CHAPTER 3 CURRENT MARKET STATUS & PIPELINE CLASSIFICATION
- Targeted therapies overview
  - The development of molecular targeted therapies
    - Current therapies are less cancer cell-specific
    - The strategy is to target the specific survival factors of a tumor
    - Key issue is the identification of targets unique to cancer cells
- Market definition
  - L1X3 - Antineoplastic monoclonal antibodies
  - L1X9 - All other antineoplastics
- Current market status
- Classification of pipeline products
  - Angiogenesis inhibitors
    - Angiogenesis as a normal biological process
    - Angiogenesis is known to be aberrant in tumor cell proliferation
    - Angiogenesis inhibitors as viable antitumor agents can target a number of pathways
    - At present, only one angiogenesis inhibitor exists on the market
  - Single-target signal transduction inhibitors
    - A plethora of potential targets exist along the signaling cascade
    - Several signal transduction inhibitors have reached the market, bringing with them their own sets of issues for consideration
  - Multi-targeted inhibitors
    - Multi-targeted inhibitors have certain advantages over single targeted agents
    - Approval of three multi-targeted inhibitors
  - Cell cycle and apoptosis targeted inhibitors
    - Only one cell cycle inhibitor has entered Phase III
    - Cell death can be induced via a number of different pathways
    - To date, only one apoptosis stimulator has reached the market
  - Epigenetic modulators
    - Despite relative immaturity of development in this class of drugs, the potential to enhance current therapies exists
  - Immunomodulatory and immunoconjugated therapeutics
    - Antibody-based technologies are an effective anticancer approach
- Oncology clinical trial design
  - Patient selection
    - Increasingly significant in the era of targeted treatment
  - Clinical trial duration
    - Sufficient follow-up is necessary to establish true clinical benefit
  - The advent of novel therapies
    - Diversity of targeted therapies will require an evolution in clinical trial design
  - Clinical trial endpoints in oncology
    - Most oncology clinical trials designate multiple endpoints
    - Survival
    - Quality of life
    - Tumor response rates
    - Toxicity
    - Time to tumor progression
CHAPTER 4 PIPELINE ANGIOGENESIS INHIBITORS ANALYSIS & FORECASTS
- Overview of angiogenesis inhibitors
  - Pipeline summary
    - Late-phase pipeline of angiogenesis inhibitors
    - Phase II pipeline of angiogenesis inhibitors
    - Phase I pipeline of angiogenesis inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Avastin (Bevacizumab; Genentech/Roche/Chugai)
- Aflibercept (VEGF-Trap; Sanofi Aventis/Regeneron)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Interim Phase II results for aflibercept in ovarian cancer
    - Interim Phase II results for aflibercept in NSCLC
    - Aflibercept demonstrates similar side effects to Avastin
  - Datamonitor comments
    - Fierce competition with Avastin in the wider cancer market
    - Presence in oncology field will aid commercialization of aflibercept
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Pazopanib (GW786034; GlaxoSmithKline)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Pazopanib as a possible second-line monotherapy treatment for metastatic RCC
    - Co-administration with Tykerb may alter the pharmacokinetics of pazopanib - Phase III studies planned
    - Pazopanib showing applicability across a broad range of solid tumor types
  - Datamonitor comments
    - Initial approval in RCC will force pazopanib to compete against the already approved Sutent and Nexavar
    - Extensive parallel development program planned
    - Tykerb may well enhance the success of pazopanib but at what price?
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Recentin (Cediranib, AZD2171; AstraZeneca)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - AstraZeneca targets first-line CRC
    - Recentin has potential in NSCLC in combination with standard chemotherapy regimens
    - Phase III study planned for Recentin in glioma
  - Datamonitor comments
    - As a potentially more potent inhibitor of angiogenesis, and given its formulation, Recentin' s future may be highly promising
    - Phase III studies in CRC are high-risk while development in glioma may offer a quicker route to market
    - AstraZeneca' s strength in the oncology market will be key in Recentin' s success
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 5 PIPELINE SINGLE-TARGET SIGNAL TRANSDUCTION INHIBITORS ANALYSIS & FORECASTS
- Overview of single-target signal transduction inhibitors
  - Pipeline summary
    - Late-phase pipeline of single-target signal transduction inhibitors
    - Phase II pipeline of single-target signal transduction inhibitors
    - Phase I pipeline of single-target signal transduction inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Gleevec (Imatinib; Novartis)
- Certican (Everolimus, RAD-001; Novartis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Certican may be a promising addition to the treatment of neuroendocrine tumors
    - Certican is also showing applicability in some of the more common tumor types
  - Datamonitor comments
    - Approval as an anticancer therapy will enable Certican to achieve a significantly higher level of sales
    - NET a good place to start
    - Novartis is an ideal backer for the drug
    - Certican may face stiff competition from Torisel
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Sarasar (Lonafarnib; Schering-Plough)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Main focus of Sarasar is development in MDS, where greatest antitumor activity is shown
    - Farnesyl transferase inhibitors predominately in hematological disorders
    - Lack of efficacy has led to termination of pivotal Phase III trial in NSCLC
    - Lack of clinical data makes it difficult to judge Sarasar' s potential in breast cancer
    - Benefit shown in advanced head and neck cancer, although no further trials have been announced
    - Mild toxicity in the majority of patients, although grade 3 events do occur
  - Datamonitor comments
    - Sarasar' s chances for approval will be delayed beyond 2007
    - Sarasar racing against Johnson & Johnson' s Zarnestra as the first farnesyl transferase inhibitor to reach the market
    - Presence in oncology market will aid commercialization of Sarasar
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- TheraCIM (Nimotuzumab; YM Bioscience)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Phase III underway for pediatric pontine (brain stem) glioma
    - Phase II pediatric trial demonstrated activity
  - Datamonitor comments
    - Phase III trial results required to verify the efficacy of this agent
    - YM Biosciences look to broaden TheraCIM' s horizons
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Xinlay (Atrasentan; Abbott Laboratories)
  - Drug overview
    - Xinlay' s target receptor plays a key role in cancer cell proliferation
  - Key historical events
  - Clinical trial data
    - FDA do not approve Xinlay for prostate cancer
    - Not the end of the road for Xinlay with new Phase III trial now underway
  - Datamonitor comments
    - Despite its rejection by the FDA, Xinlay' s future may still be promising
    - Abbott' s favorable position in the prostate cancer market will be invaluable
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zalutumumab (HuMax-EGFR; Genmab)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - With Fast Track status granted, SCCHN offers promise as a lead indication for zalutumumab
  - Datamonitor comments
    - A head-to-head study against Erbitux could work in zalutumumab' s favor
    - Zalutumumab will need to be competitively priced
    - Zalutumumab may also have to compete with Tarceva and Iressa
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zarnestra (Tipifarnib; Johnson & Johnson)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Following rejection of NDA, the FDA requires Phase III data for Zarnestra in AML before regulatory approval can be considered
    - Results from Phase III studies have yet to be announced
    - Zarnestra has demonstrated a favorable profile in Phase II studies
    - Single-agent Zarnestra demonstrates antitumor activity in relapsed/refractory aggressive NHL
    - Zarnestra holding promise in juvenile myelomonocytic leukemia
    - Following modest activity in brain cancer, further trials have been initiated
    - Negative Phase III trial results cause termination of development in pancreatic and colorectal cancer
  - Datamonitor comments
    - Schering-Plough' s Sarasar catching up with Zarnestra as the first farnesyl transferase inhibitor to reach the market
    - Johnson & Johnson limiting Zarnestra' s target population in the short term
    - Johnson & Johnson' s experience will be invaluable to Zarnestra
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 6 PIPELINE MULTI-TARGETED INHIBITORS ANALYSIS & FORECASTS
- Overview of multi-targeted inhibitors
  - Pipeline summary
    - Late-phase pipeline of multi-targeted inhibitors
    - Phase II pipeline of multi-targeted inhibitors
    - Phase I pipeline of multi-targeted inhibitors
  - Comparative forecasts
  - Definition of current comparator therapy
    - Gleevec (Imatinib; Novartis)
- Tasigna (Nilotinib, AMN-107; Novartis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Tasigna awaiting approval in the US, the EU and Japan for Gleevec-resistant CML
    - Promising Phase II data reported
    - Tasigna appears effective in CML patients who have failed or are intolerant to both Gleevec and Sprycel
    - Only one Bcr-Abl mutation is insensitive to Tasigna
    - Tasigna shows promise for Gleevec-resistant metastatic GIST patients
  - Datamonitor comments
    - Tasigna ready to challenge Bristol-Myers Squibb' s already approved Sprycel
    - Novartis looking to expand its leading role in the CML therapy market
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Axitinib (AG-13736; Pfizer)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Phase III trial warranted in pancreatic cancer following a 26% reduction in the risk of death when axitinib is added to Gemzar - Phase II results
    - Axitinib demonstrates impressive activity in thyroid cancer. Phase III trial yet to start
    - Axitinib also making encouraging progress in other popular tumor types
  - Datamonitor comments
    - A similar response rate to Tarceva in pancreatic cancer means approval will be likely
    - Axitinib will enjoy the global presence and unparalleled marketing strength Pfizer can offer
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Ceflatonin (Myelostat; ChemGenex Pharmaceuticals)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Ceflatonin aims to restore Gleevec sensitivity in CML patients
    - ChemGenex looking to expand Ceflatonin into the AML/APL market
  - Datamonitor comments
    - Despite convincing clinical benefit, Ceflatonin will face strong competition from Bristol-Myers Squibb' s Sprycel and Novartis' s Tasigna
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Enzastaurin (LY317615; Eli Lilly)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Enzastaurin looking to make its mark in the B-cell lymphoma market
    - Enzastaurin holding promise as a maintenance therapy in mantle cell lymphoma
    - Despite discontinuation of a Phase III trial in Glioma, Eli Lilly has initiated 20 additional clinical trials
  - Datamonitor comments
    - Eli Lilly adopt a risky strategy for enzastaurin in DLBCL
    - Termination of Phase III trial for enzastaurin in glioma may hamper its potential in other indications
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Lestaurtinib (CEP-701; Cephalon)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Lestaurtinib emerging as a promising agent for AML patients harboring Flt-3 activating mutations
  - Datamonitor comments
    - Lestaurtinib may be the first in its class to reach the market
    - Cephalon' s recent acquisition of Trisenox will provide valuable experience of the leukemia market
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zactima (Vandetanib, ZD6474; AstraZeneca)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Zactima granted Orphan Drug designation and Fast Track status for Thyroid cancer
    - Multiple Phase III trials for Zactima underway in NSCLC
    - Zactima fails to demonstrate efficacy as a maintenance therapy for SCLC
  - Datamonitor comments
    - Zactima set to enjoy a monopoly of thyroid cancer niche market
    - Zactima being pushed through the clinical development process for NSCLC
    - Zactima offers product differentiation with unique multi-targeted characteristics
    - AstraZeneca' s strength in the oncology market will be key in Zactima' s success
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 7 PIPELINE CELL CYCLE AND APOPTOSIS TARGETED AGENTS ANALYSIS & FORECASTS
- Overview of cell cycle and apoptosis targeted agents
  - Pipeline summary
    - Late-phase pipeline of cell cycle and apoptosis targeted agents
    - Phase II pipeline of cell cycle and apoptosis targeted agents
    - Phase I pipeline of cell cycle and apoptosis targeted agents
  - Comparative forecasts
  - Definition of current comparator therapy
    - Velcade (Bortezomib; Millennium Pharmaceuticals)
- Alvocidib (Flavopiridol; Sanofi-Aventis)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Continuous infusion dosing schedules fail to demonstrate clinical activity
    - Modified dosing regimen drives further development in CLL
  - Datamonitor comments
    - Given alvocidib' s checkered history, Sanofi-Aventis may face an uphill struggle communicating the drug' s potential
    - Alvocidib may show more promise as part of a combination regimen
    - Presence in oncology field will aid commercialization of alvocidib
- Genasense (Oblimersen; Genta)
  - Drug overview
  - Key historical events
  - Datamonitor comments
    - Approval of Genasense is looking increasingly unlikely
    - Termination of agreement with Sanofi-Aventis is a major setback for Genta
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Phenoxodiol (Novogen)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - The OVATURE trials
    - The combination of phenoxodiol and cisplatin is particularly effective in ovarian cancer
  - Datamonitor comments
    - Toxicity will be the key factor for phenoxodiol' s success
    - Sanofi-Aventis as a marketing partner?
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 8 PIPELINE IMMUNOMODULATORY AND IMMUNOCONJUGATED THERAPEUTICS ANALYSIS & FORECASTS
- Overview of immunomodulatory and immunoconjugated therapeutics
  - Pipeline summary
    - Late-phase pipeline of immunomodulatory and immunoconjugated therapeutics
    - Phase II pipeline of immunomodulatory and immunoconjugated therapeutics
    - Phase I pipeline of immunomodulatory and immunoconjugated therapeutics
  - Comparative forecasts
  - Definition of current comparator therapy
    - Rituxan (Rituximab; Biogen Idec/Genentech/Roche)
- Galiximab (Anti-CD80 MAb; Biogen Idec)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Randomized Phase III trial will compare survival of galiximab plus Rituxan with Rituxan alone in relapsed/refractory follicular NHL patients
    - Phase II results show galiximab and Rituxan can be safely combined and can produce promising response rates in follicular NHL patients
  - Datamonitor comments
    - Biogen Idec in a strong position to successfully market galiximab alone
    - Biogen-Idec will need to effectively demonstrate the value of a combination of galiximab and Rituxan to payers
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Lumiliximab (Anti-CD23 MAb; Biogen Idec)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - The addition of lumiliximab to the FCR regimen may produce a higher response rate without additional toxicity
  - Datamonitor comments
    - Lumiliximab on course to become an established addition to the standard treatment for CLL
    - Biogen Idec should look to investigate Lumiliximab as a maintenance therapy
    - Cluster of Differentiation (CD) drugs have become Biogen Idec' s specialty
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Ofatumumab (HuMax-CD20; Genmab/GlaxoSmithKline)
  - Drug overview
    - Genmab hoping ofatumumab will demonstrate a preferred efficacy profile over Rituxan in the clinic
  - Key historical events
  - Clinical trial data
    - Ofatumumab receives Fast Track status for CLL and enters a Phase III trial
    - Genmab initiates a pivotal Phase III trial in follicular NHL
  - Datamonitor comments
    - Ofatumumab may offer hope for Rituxan-insensitive patients
    - Approval of other MAbs being developed by Biogen Idec for NHL and CLL may restrict ofatumumab' s potential even further
    - GlaxoSmithKline will offer invaluable experience to Genmab and aid commercialization of ofatumumab
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Proxinium/Vicinium (VB4-845; Viventia Biotech)
  - Drug overview
    - An ' armed' antibody for the potential treatment of head and neck, and bladder cancer
  - Key historical events
  - Clinical trial data
    - Proxinium shows a good safety profile and preliminary evidence of clinical efficacy in Phase I trials in head and neck cancer
    - Vicinium also making headway in bladder cancer
  - Datamonitor comments
    - The requirement for EpCAM expression may limit Proxinium' s uptake
    - Proxinium will have to compete with Erbitux
    - Viventia should look to investigate Proxinium in combination with radiotherapy
    - BCG failure creates a commercial opportunity for Vicinium
    - Vicinium may face competitive pressure from novel intravesical chemotherapies in the near future
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Rencarex (WX-G250; Wilex)
  - Drug overview
    - MN/CA IX Antigen - A highly specific tumor target
    - Mode of Action of Rencarex - ADCC
  - Key historical events
  - Clinical trial data
    - Completed Phase I & II trials for metastatic RCC
    - In patients responding to treatment, Rencarex monotherapy improves survival
    - The combination with IFN is well-tolerated and of clinical benefit in metastatic RCC
  - Datamonitor comments
    - The high recurrence rate for RCC creates a commercial opportunity
    - Rencarex may face a number of hurdles
  - Forecasts to 2016
  - Datamonitor drug assessment summary
- Zanolimumab (HuMax-CD4; Genmab)
  - Drug overview
  - Key historical events
  - Clinical trial data
    - Zanolimumab' s Orphan Drug and Fast Track status reflects the high unmet needs in CTCL
    - Zanolimumab may also hold promise for PTCL patients
  - Datamonitor comments
    - The T-cell lymphoma market offers zanolimumab a limited commercial potential
    - Depletion of CD4+ T-cells by zanolimumab may render the patient susceptible to opportunistic infections
  - Forecasts to 2016
  - Datamonitor drug assessment summary
CHAPTER 9 PIPELINE EPIGENETIC MODULATORS ANALYSIS & FORECASTS
- Overview of epigenetic modulators
  - Pipeline summary
    - Late-phase pipeline of epigenetic modulators
    - Phase II pipeline of epigenetic modulators
    - Phase I pipeline of epigenetic modulators
APPENDIX
- List of tables
- List of figures
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
- Abbreviations
- Contributing experts
- Bibliography
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
- List of Tables
  - Table 1: Late-phase pipeline molecular targeted cancer therapies, 2007
  - Table 2: Phase II pipeline molecular targeted cancer therapies, 2007
  - Table 3: Phase I pipeline molecular targeted cancer therapies, 2007
  - Table 4: Pipeline molecular targeted therapies by development phase and class of drug, 2007
  - Table 5: Pipeline molecular targeted therapies by indication, 2007
  - Table 6: Potential anticancer molecular targets being exploited by only one candidate in the clinical development pipeline, 2007
  - Table 7: Potential anticancer molecular targets being exploited by two candidates in the clinical development pipeline, 2007
  - Table 8: Potential anticancer molecular targets being exploited by three candidates in the clinical development pipeline, 2007
  - Table 9: Pfizer' s marketed cancer portfolio, 2007
  - Table 10: Pfizer' s molecular targeted cancer therapies pipeline, 2007
  - Table 11: AstraZeneca' s marketed cancer portfolio, 2007
  - Table 12: AstraZeneca' s molecular targeted cancer therapies pipeline, 2007
  - Table 13: Novartis' s marketed cancer portfolio, 2007
  - Table 14: Novartis' s molecular targeted cancer therapies pipeline, 2007
  - Table 15: Late-phase pipeline molecular targeted therapy products sales forecasts in the seven major markets ($m), 2007-2016
  - Table 16: Currently approved molecular targeted cancer therapies, 2007
  - Table 17: Examples of naturally occurring angiogenesis stimulators
  - Table 18: Recently approved multi-targeted inhibitors, 2007
  - Table 19: Late-phase pipeline angiogenesis inhibitors, 2007
  - Table 20: Phase II pipeline angiogenesis inhibitors, 2007
  - Table 21: Phase I pipeline angiogenesis inhibitors, 2007
  - Table 22: Forecasting assumptions for late-phase angiogenesis inhibitors in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 23: Forecasting assumptions for late-phase angiogenesis inhibitors in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 24: Avastin: Key facts
  - Table 25: Aflibercept: Key historical events
  - Table 26: Ongoing clinical trials involving aflibercept, 2007
  - Table 27: Interim Phase II results for aflibercept in NSCLC
  - Table 28: Forecasting assumptions for aflibercept in the seven major pharmaceutical markets, 2007
  - Table 29: Aflibercept 7MM sales forecast in second-line ovarian cancer, second-line NSCLC and second-line HRPC ($m), 2007-2016
  - Table 30: Pazopanib: Key historical events
  - Table 31: Ongoing clinical trials involving pazopanib, 2007
  - Table 32: Phase II interim analysis for pazopanib monotherapy in second-line RCC at 12 weeks
  - Table 33: Phase II interim analysis for pazopanib monotherapy in relapsed soft tissue sarcoma at 12 weeks
  - Table 34: Phase II interim analysis for pazopanib monotherapy in high-risk relapsed ovarian cancer at 12 weeks
  - Table 35: Forecasting assumptions for pazopanib in the seven major pharmaceutical markets, 2007
  - Table 36: Pazopanib 7MM sales forecast in first/second-line RCC and second-line Her2+ breast cancer ($m), 2007-2016
  - Table 37: Recentin: Key historical events
  - Table 38: Ongoing clinical trials involving Recentin, 2007
  - Table 39: Phase I results of Recentin plus standard chemotherapy in NSCLC
  - Table 40: Forecasting assumptions for Recentin in the seven major pharmaceutical markets, 2007
  - Table 41: Recentin 7MM sales forecast in first-line NSCLC, first-line CRC and recurrent/ progressive glioma ($m), 2007-2016
  - Table 42: Late-phase pipeline single-target signal transduction inhibitors, 2007
  - Table 43: Phase II pipeline single-target signal transduction inhibitors, 2007
  - Table 44: Phase I pipeline single-target signal transduction inhibitors, 2007
  - Table 45: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (1 of 3)
  - Table 46: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (2 of 3)
  - Table 47: Forecasting assumptions for late-phase single-target signal transduction inhibitors in the seven major pharmaceutical markets, 2007 (3 of 3)
  - Table 48: Gleevec: Key facts
  - Table 49: Certican: Key historical events
  - Table 50: Ongoing clinical trials involving Certican, 2007
  - Table 51: Phase II study results for Certican plus octreotide in NET
  - Table 52: Interim Phase II results of Certican monotherapy in metastatic RCC
  - Table 53: Interim Phase II results of Certican monotherapy in lymphoma
  - Table 54: Forecasting assumptions for Certican in the seven major pharmaceutical markets, 2007
  - Table 55: Certican 7MM sales forecast in second-line NET, second-line RCC, salvage therapy CRC and second-line GIST ($m), 2007-2016
  - Table 56: Sarasar: Key historical events
  - Table 57: Ongoing clinical trials involving Sarasar, 2007
  - Table 58: Phase I/II study results of Sarasar monotherapy in advanced MDS and CMML (1 of 2)
  - Table 59: Phase I/II study results of Sarasar monotherapy in advanced MDS and CMML (2 of 2)
  - Table 60: Phase II results of Sarasar in Head and Neck cancer
  - Table 61: Forecasting assumptions for Sarasar in the seven major pharmaceutical markets, 2007
  - Table 62: Sarasar 7MM sales forecast in second-line MDS ($m), 2007-2016
  - Table 63: TheraCIM: Key historical events
  - Table 64: Ongoing clinical trials involving TheraCIM, 2007
  - Table 65: Forecasting assumptions for TheraCIM in the seven major pharmaceutical markets, 2007
  - Table 66: TheraCIM 7MM sales forecast in first-line glioma ($m), 2007-2016
  - Table 67: Xinlay: Key historical events
  - Table 68: Ongoing clinical trials involving Xinlay, 2007
  - Table 69: Meta-analysis of pooled data from two randomized Phase III trials (M96-594 and M00-211) of Xinlay versus placebo in metastatic HRPC
  - Table 70: Forecasting assumptions for Xinlay in the seven major pharmaceutical markets, 2007
  - Table 71: Xinlay 7MM sales forecast in first-line metastatic HRPC ($m), 2007-2016
  - Table 72: Zalutumumab: Key historical events
  - Table 73: Ongoing clinical trials involving zalutumumab, 2007
  - Table 74: Phase I/II study results of zalutumumab in recurrent SCCHN
  - Table 75: Forecasting assumptions for zalutumumab in the seven major pharmaceutical markets, 2007
  - Table 76: Zalutumumab 7MM sales forecast in first/second-line SCCHN ($m), 2007-2016
  - Table 77: Zarnestra: Key historical events
  - Table 78: Ongoing clinical trials involving Zarnestra, 2007
  - Table 79: Phase I/II study of Zarnestra in combination with chemotherapy in newly diagnosed AML or high-risk MDS patients
  - Table 80: Phase II results for Zarnestra in elderly, previously untreated poor-risk AML patients who were not suitable for chemotherapy
  - Table 81: Phase II results of Zarnestra monotherapy in relapsed/refractory aggressive NHL, 2006
  - Table 82: Phase II study results of Zarnestra in juvenile myelomonocytic leukemia (JMML), 2005
  - Table 83: Phase I/II trial involving Nexavar, Tarceva, Torisel and Zarnestra, 2006
  - Table 84: Phase III trial results of Zarnestra in pancreatic cancer
  - Table 85: Phase III trial results of Zarnestra in CRC
  - Table 86: Forecasting assumptions for Zarnestra in the seven major pharmaceutical markets, 2007
  - Table 87: Zarnestra 7MM sales forecasts in first-line elderly AML ($m), 2007-2016
  - Table 88: Late-phase pipeline multi-targeted inhibitors, 2007
  - Table 89: Phase II pipeline multi-targeted inhibitors, 2007
  - Table 90: Phase I pipeline multi-targeted inhibitors, 2007
  - Table 91: Forecasting assumptions for late-phase multi-targeted inhibitors in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 92: Forecasting assumptions for late-phase multi-targeted inhibitors in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 93: Gleevec: Key facts
  - Table 94: Tasigna: Key historical events
  - Table 95: Ongoing clinical trials involving Tasigna, 2007
  - Table 96: Trial design and clinical outcomes for a small patient subgroup from the ENACT trial
  - Table 97: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in chronic phase
  - Table 98: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in accelerated phase
  - Table 99: Phase II results for Tasigna in Gleevec-resistant or intolerant patients with CML in blast crisis phase or relapsed/refractory Ph+ ALL
  - Table 100: Phase II results for Tasigna in hypereosinophilic syndrome (HES)
  - Table 101: Phase II results for Tasigna in systemic mastocytosis
  - Table 102: Phase II results for Tasigna in Gleevec and Sprycel-resistant or intolerant patients with CML in all stages of the disease
  - Table 103: Phase I results for Tasigna with or without Gleevec in Gleevec-resistant GIST
  - Table 104: Forecasting assumptions for Tasigna in the seven major pharmaceutical markets, 2007
  - Table 105: Tasigna sales forecast in Gleevec-refractory CML and third-line GIST ($m), 2007-2016
  - Table 106: Axitinib: Key historical events
  - Table 107: Ongoing clinical trials involving axitinib, 2007
  - Table 108: Phase II results for axitinib in thyroid cancer
  - Table 109: Phase II results for axitinib in Nexavar-refractory mRCC
  - Table 110: Phase II results for axitinib in relapsed NSCLC
  - Table 111: Forecasting assumptions for axitinib in the seven major pharmaceutical markets, 2007
  - Table 112: Axitinib 7MM sales forecast in first-line pancreatic cancer and second-line thyroid cancer ($m), 2007-2016
  - Table 113: Ceflatonin: Key historical events
  - Table 114: Ongoing clinical trials involving Ceflatonin, 2007
  - Table 115: Interim data for Ceflatonin monotherapy in patients with Gleevec-refractory CML harboring the T315I Bcr-Abl point mutation
  - Table 116: Phase II trial outline for Ceflatonin plus Gleevec in Gleevec-refractory patients
  - Table 117: Interim data for Ceflatonin in combination with Gleevec in patients with Gleevec-refractory CML
  - Table 118: Forecasting assumptions for Ceflatonin in the seven major pharmaceutical markets, 2007
  - Table 119: Ceflatonin 7MM sales forecast in Gleevec-resistant CML ($m), 2007-2016
  - Table 120: Enzastaurin: Key historical events
  - Table 121: Ongoing clinical trials involving enzastaurin, 2007
  - Table 122: Phase II results of enzastaurin in relapsed DLBCL
  - Table 123: Phase II results of enzastaurin in relapsed MCL
  - Table 124: Phase II results of enzastaurin in second/third-line NSCLC
  - Table 125: Forecasting assumptions for enzastaurin in the seven major pharmaceutical markets, 2007
  - Table 126: Enzastaurin 7MM sales forecast as a maintenance therapy in DLBCL ($m), 2007-2016
  - Table 127: Lestaurtinib: Key historical events
  - Table 128: Ongoing clinical trial involving lestaurtinib, 2007
  - Table 129: Interim Phase II/III results of lestaurtinib and chemotherapy in patients with relapsed AML harboring Flt-3 activating mutations
  - Table 130: Forecasting assumptions for lestaurtinib in the seven major pharmaceutical markets, 2007
  - Table 131: Lestaurtinib 7MM sales forecast in second-line AML ($m), 2007-2016
  - Table 132: Zactima' s multiple anticancer targets
  - Table 133: Zactima: Key historical events
  - Table 134: Ongoing clinical trials involving Zactima, 2007
  - Table 135: Phase II results for Zactima monotherapy in metastatic hereditary medullary thyroid cancer
  - Table 136: Phase II results for Zactima plus chemotherapy in first-line NSCLC
  - Table 137: Phase II results for Zactima plus Taxotere in second-line NSCLC
  - Table 138: Phase I results for Zactima plus Alimta in second-line NSCLC
  - Table 139: Forecasting assumptions for Zactima in the seven major pharmaceutical markets, 2007
  - Table 140: Zactima 7MM sales forecast in NSCLC ($m), 2007-2016
  - Table 141: Late-phase pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 142: Phase II pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 143: Phase I pipeline cell cycle and apoptosis targeted agents, 2007
  - Table 144: Forecasting assumptions for late-phase cell cycle and apoptosis targeted agents in the seven major pharmaceutical markets, 2007
  - Table 145: Velcade: Key facts
  - Table 146: Alvocidib: Key historical events
  - Table 147: Ongoing clinical trials involving alvocidib, 2007
  - Table 148: Genasense: Key historical events
  - Table 149: Forecasting assumptions for Genasense in the seven major pharmaceutical markets, 2007
  - Table 150: Genasense 7MM sales forecast in first-line elderly AML and first-line metastatic melanoma ($m), 2007-2016
  - Table 151: Phenoxodiol: Key historical events
  - Table 152: Ongoing clinical trials involving phenoxodiol, 2007
  - Table 153: Forecasting assumptions for phenoxodiol in the seven major pharmaceutical markets, 2007
  - Table 154: Phenoxodiol 7MM sales forecast in third-line ovarian cancer ($m), 2007-2016
  - Table 155: Late-phase pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 156: Phase II pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 157: Phase I pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Table 158: Forecasting assumptions for late-phase immunomodulatory and immunoconjugated therapeutics in the seven major pharmaceutical markets, 2007 (1 of 2)
  - Table 159: Forecasting assumptions for late-phase immunomodulatory and immunoconjugated therapeutics in the seven major pharmaceutical markets, 2007 (2 of 2)
  - Table 160: Approved indications for Rituxan in the US and EU, 2006
  - Table 161: Rituxan: Key facts
  - Table 162: Galiximab: Key historical events
  - Table 163: Ongoing clinical trial involving galiximab, 2007
  - Table 164: Phase II study of galiximab in combination with Rituxan in relapsed/refractory follicular NHL
  - Table 165: Retrospective comparison of galiximab plus Rituxan with Rituxan monotherapy in relapsed/refractory follicular NHL
  - Table 166: Forecasting assumptions for galiximab in the seven major pharmaceutical markets, 2007
  - Table 167: Galiximab 7MM sales forecast in follicular NHL ($m), 2007-2016
  - Table 168: Lumiliximab: Key historical events
  - Table 169: Ongoing clinical trial involving lumiliximab, 2007
  - Table 170: Comparison of results from a Phase I/II study of lumiliximab in combination with FCR in relapsed/refractory CLL
  - Table 171: Biogen Idec' s Cluster of Differentiation (CD) targeted drugs, 2007
  - Table 172: Forecasting assumptions for lumiliximab in the seven major pharmaceutical markets, 2007
  - Table 173: Lumiliximab 7MM sales forecast in relapsed/refractory CLL ($m), 2007-2016
  - Table 174: Ofatumumab: Key historical events
  - Table 175: Ongoing clinical trial involving ofatumumab, 2007
  - Table 176: Phase I/II results of ofatumumab in relapsed/refractory CLL
  - Table 177: Interim Phase I/II results of ofatumumab in relapsed/refractory follicular NHL
  - Table 178: Phase I/II adverse events data from ofatumumab in relapsed/refractory follicular NHL
  - Table 179: GlaxoSmithKline' s marketed oncology portfolio, 2007
  - Table 180: Forecasting assumptions for ofatumumab in the seven major pharmaceutical markets, 2007
  - Table 181: Ofatumumab 7MM sales forecast in relapsed/refractory CLL and second-line follicular NHL ($m), 2007-2016
  - Table 182: Proxinium: Key historical events
  - Table 183: Ongoing clinical trials involving Proxinium, 2007
  - Table 184: Forecasting assumptions for Proxinium in the seven major pharmaceutical markets, 2007
  - Table 185: Proxinium 7MM sales forecast in second-line SCCHN ($m), 2007-2016
  - Table 186: Rencarex: Key historical events
  - Table 187: Ongoing clinical trials involving Rencarex, 2007
  - Table 188: Phase I/II study of Rencarex plus IFN in metastatic RCC
  - Table 189: Ongoing Phase III trials in the adjuvant RCC setting
  - Table 190: Forecasting assumptions for Rencarex in the seven major pharmaceutical markets, 2007
  - Table 191: Rencarex 7MM sales forecast in adjuvant RCC ($m), 2007-2016
  - Table 192: Zanolimumab: Key historical events
  - Table 193: Ongoing clinical trial involving zanolimumab, 2007
  - Table 194: Phase II results of zanolimumab in mycosis fungoides CTCL
  - Table 195: Interim Phase II results of zanolimumab in PTCL patients
  - Table 196: Forecasting assumptions for zanolimumab in the seven major pharmaceutical markets, 2007
  - Table 197: Zanolimumab 7MM sales forecast in relapsed CTCL ($m), 2007-2016
  - Table 198: Zolinza: Key facts
  - Table 199: Phase II pipeline epigenetic modulators, 2007
  - Table 200: Phase I pipeline epigenetic modulators, 2007
  - Table 201: Datamonitor drug assessment parameters
  - Table 202: Abbreviations used in Pipeline Insight: Molecular Targeted Cancer Therapies
- List of Figures
  - Figure 1: Pipeline molecular targeted therapies by development phase and class of drug, 2007
  - Figure 2: Pipeline molecular targeted therapies by class of drug, 2007
  - Figure 3: Pipeline molecular targeted therapies by development phase, 2007
  - Figure 4: Angiogenesis inhibitors by developmental phase, 2007
  - Figure 5: Single-target signal transduction inhibitors by developmental phase, 2007
  - Figure 6: Multi-targeted inhibitors by developmental phase, 2007
  - Figure 7: Cell cycle and apoptosis targeted agents by developmental phase, 2007
  - Figure 8: Immunomodulatory and immunoconjugated therapeutics by developmental phase, 2007
  - Figure 9: Epigenetic modulators by developmental phase, 2007
  - Figure 10: Pipeline molecular targeted therapies by indication, 2007
  - Figure 11: Pipeline molecular targeted therapies by hematological malignancy, 2007
  - Figure 12: Potential anticancer molecular targets being exploited by four or more candidates in the clinical development pipeline, 2007
  - Figure 13: Molecular targeted therapies product pipeline by type of company, 2007
  - Figure 14: Segmentation of companies according to number of products in the MTT pipeline, 2007
  - Figure 15: Companies with MTT candidates in late-phase development, 2007
  - Figure 16: Companies with four or more candidates in the molecular targeted therapies pipeline, 2007
  - Figure 17: Pipeline angiogenesis inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 18: Pipeline single-target signal transduction inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 19: Pipeline multi-targeted inhibitors sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 20: Pipeline cell cycle and apoptosis targeted agents sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 21: Pipeline immunomodulatory and immunoconjugated therapeutics sales forecasts across the seven major markets ($m), 2007-2016
  - Figure 22: Clinical and commercial attractiveness of pipeline angiogenesis inhibitors, 2007
  - Figure 23: Clinical and commercial attractiveness of pipeline single-target signal transduction inhibitors, 2007
  - Figure 24: Clinical and commercial attractiveness of pipeline multi-targeted inhibitors, 2007
  - Figure 25: Clinical and commercial attractiveness of pipeline cell cycle and apoptosis targeted agents, 2007
  - Figure 26: Clinical and commercial attractiveness of pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Figure 27: The process of tumor angiogenesis
  - Figure 28: Clinical and commercial attractiveness of pipeline angiogenesis inhibitors, 2007
  - Figure 29: Pipeline angiogenesis inhibitors sales forecasts in the seven major markets ($m), 2007-2016
  - Figure 30: Interim Phase II results of aflibercept in ovarian cancer
  - Figure 31: Aflibercept 7MM sales forecast in second-line ovarian cancer, second-line NSCLC and second-line HRPC ($m), 2007-2016
  - Figure 32: Clinical and commercial attractiveness of aflibercept, 2007
  - Figure 33: Pazopanib' s mode of action
  - Figure 34: Phase III study design for pazopanib monotherapy in second-line RCC
  - Figure 35: Phase II study design for pazopanib monotherapy in second-line RCC
  - Figure 36: Phase II study design for pazopanib monotherapy in relapsed soft tissue sarcoma
  - Figure 37: Phase II study design for pazopanib monotherapy in high-risk relapsed ovarian cancer
  - Figure 38: Pazopanib 7MM sales forecast in first/second-line RCC and second-line Her2+ breast cancer ($m), 2007-2016
  - Figure 39: Clinical and commercial attractiveness of pazopanib, 2007
  - Figure 40: Recentin (cediranib; AZD2171) mode of action
  - Figure 41: Phase I interim results for Recentin in second-line CRC
  - Figure 42: HORIZON II and HORIZON III clinical trials designs involving Recentin in first-line CRC
  - Figure 43: Recentin 7MM sales forecast in first-line NSCLC, first-line CRC and recurrent/ progressive glioma ($m), 2007-2016
  - Figure 44: Clinical and commercial attractiveness of Recentin, 2007
  - Figure 45: Clinical and commercial attractiveness of pipeline single-target signal transduction inhibitors, 2007
  - Figure 46: Pipeline single-target signal transduction inhibitors sales forecasts in the seven major markets ($m), 2007-2016
  - Figure 47: Phase II results of Certican monotherapy in breast cancer
  - Figure 48: Phase II results of Certican monotherapy in NSCLC
  - Figure 49: Certican 7MM sales forecast in second-line NET, second-line RCC, salvage therapy CRC and second-line GIST ($m), 2007-2016
  - Figure 50: Clinical and commercial attractiveness of Certican, 2007
  - Figure 51: Sarasar 7MM sales forecast in second-line MDS ($m), 2007-2016
  - Figure 52: Clinical and commercial attractiveness of Sarasar, 2007
  - Figure 53: Phase II trial results for TheraCIM in pediatric glioma
  - Figure 54: TheraCIM 7MM sales forecast in first-line glioma ($m), 2007-2016
  - Figure 55: Clinical and commercial attractiveness of TheraCIM, 2007
  - Figure 56: Clinical trial design for the recently initiated Phase III trial involving Xinlay in HRPC
  - Figure 57: Xinlay 7MM sales forecast in first-line metastatic HRPC ($m), 2007-2016
  - Figure 58: Clinical and commercial attractiveness of Xinlay, 2007
  - Figure 59: Types of monoclonal antibodies
  - Figure 60: Zalutumumab 7MM sales forecast in first/second-line SCCHN ($m), 2007-2016
  - Figure 61: Clinical and commercial attractiveness of zalutumumab, 2007
  - Figure 62: Phase I/II trial design of Zarnestra in combination with chemotherapy in newly diagnosed AML or high-risk MDS patients
  - Figure 63: Zarnestra 7MM sales forecasts in first-line elderly AML ($m), 2007-2016
  - Figure 64: Clinical and commercial attractiveness of Zarnestra, 2007
  - Figure 65: Clinical and commercial attractiveness of pipeline multi-targeted inhibitors, 2007
  - Figure 66: Pipeline multi-targeted inhibitors sales forecasts ($m), 2007-2016
  - Figure 67: Phase I study outline for Tasigna with or without Gleevec in Gleevec-resistant GIST
  - Figure 68: Tasigna sales forecast in Gleevec-refractory CML and third-line GIST ($m), 2007-2016
  - Figure 69: Clinical and commercial attractiveness of Tasigna, 2007
  - Figure 70: Phase II results for axitinib plus Gemzar in first-line pancreatic cancer
  - Figure 71: Randomized Phase II study results for axitinib plus Taxotere in first-line metastatic breast cancer
  - Figure 72: Axitinib 7MM sales forecast in first-line pancreatic cancer and second-line thyroid cancer ($m), 2007-2016
  - Figure 73: Clinical and commercial attractiveness of axitinib, 2007
  - Figure 74: Phase II/III trial for Ceflatonin in Gleevec-refractory CML
  - Figure 75: Ceflatonin 7MM sales forecast in Gleevec-resistant CML ($m), 2007-2016
  - Figure 76: Clinical and commercial attractiveness of Ceflatonin, 2007
  - Figure 77: Enzastaurin 7MM sales forecast as a maintenance therapy in DLBCL ($m), 2007-2016
  - Figure 78: Clinical and commercial attractiveness of enzastaurin, 2007
  - Figure 79: Lestaurtinib 7MM sales forecast in second-line AML ($m), 2007-2016
  - Figure 80: Clinical and commercial attractiveness of lestaurtinib, 2007
  - Figure 81: Phase II results for maintenance Zactima in SCLC
  - Figure 82: Zactima 7MM sales forecast in NSCLC ($m), 2007-2016
  - Figure 83: Clinical and commercial attractiveness of Zactima, 2007
  - Figure 84: Clinical and commercial attractiveness of pipeline cell cycle and apoptosis targeted agents, 2007
  - Figure 85: Pipeline cell cycle and apoptosis targeted agents sales forecasts ($m), 2007-2016
  - Figure 86: Phase I results for alvocidib monotherapy in CLL
  - Figure 87: Phase II results for alvocidib plus chemotherapy in acute leukemias
  - Figure 88: Genasense 7MM sales forecast in first-line elderly AML and first-line metastatic melanoma ($m), 2007-2016
  - Figure 89: Clinical and commercial attractiveness of Genasense, 2007
  - Figure 90: Phase II results for phenoxodiol plus chemotherapy in resistant/refractory ovarian cancer
  - Figure 91: Phenoxodiol 7MM sales forecast in third-line ovarian cancer ($m), 2007-2016
  - Figure 92: Clinical and commercial attractiveness of phenoxodiol, 2007
  - Figure 93: Clinical and commercial attractiveness of pipeline immunomodulatory and immunoconjugated therapeutics, 2007
  - Figure 94: Pipeline immunomodulatory and immunoconjugated therapeutics sales forecasts ($m), 2007-2016
  - Figure 95: Galiximab 7MM sales forecast in follicular NHL ($m), 2007-2016
  - Figure 96: Clinical and commercial attractiveness of galiximab, 2007
  - Figure 97: Phase I/II study design for lumiliximab in combination with FCR in relapsed/refractory CLL
  - Figure 98: Lumiliximab 7MM sales forecast in relapsed/refractory CLL ($m), 2007-2016
  - Figure 99: Clinical and commercial attractiveness of lumiliximab, 2007
  - Figure 100: Phase III study design for ofatumumab in patients with CLL refractory to both fludarabine and Campath
  - Figure 101: Phase III study design for ofatumumab in Rituxan-refractory follicular NHL
  - Figure 102: Ofatumumab 7MM sales forecast in relapsed/refractory CLL and second-line follicular NHL ($m), 2007-2016
  - Figure 103: Clinical and commercial attractiveness of ofatumumab, 2007
  - Figure 104: Phase I results for Proxinium in advanced SCCHN
  - Figure 105: Phase I/II results for Vicinium in superficial TCC of the bladder
  - Figure 106: Proxinium 7MM sales forecast in second-line SCCHN ($m), 2007-2016
  - Figure 107: Clinical and commercial attractiveness of Proxinium, 2007
  - Figure 108: Rencarex induced ADCC
  - Figure 109: Phase II study design for Rencarex monotherapy in advanced RCC
  - Figure 110: Rencarex Phase II results: median survival
  - Figure 111: Phase I/II study design for Rencarex plus IFN in metastatic RCC
  - Figure 112: Rencarex 7MM sales forecast in adjuvant RCC ($m), 2007-2016
  - Figure 113: Clinical and commercial attractiveness of Rencarex, 2007
  - Figure 114: Phase III study design for zanolimumab in CTCL
  - Figure 115: Preliminary results for the first stage of the Phase III study for zanolimumab in CTCL
  - Figure 116: Zanolimumab 7MM sales forecast in relapsed CTCL ($m), 2007-2016
  - Figure 117: Clinical and commercial attractiveness of zanolimumab, 2007
  - Figure 118: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007

癌の分子標的治療

Pipeline Insight: Molecular Targeted Cancer Therapies - Can anything else revolutionize the market?

Abstract

Overview

Introduction

Scope

Report Highlights

Reasons to Purchase

Table of Contents